Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

This publication has 11 references indexed in Scilit:

• Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin
  Circulation, 2001
• Low-molecular-weight heparins in the treatment of acute coronary syndromes.
  Archives of internal medicine (1960), 2001
• Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial
  The Lancet, 2001
• The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study
  Clinical Cardiology, 2001
• Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial Infarction
  Circulation, 2000
• 1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations
  Circulation, 1999
• Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial
  The Lancet, 1999
• Abciximab Facilitates the Rate and Extent of Thrombolysis
  Circulation, 1999
• Thrombolysis for Acute Myocardial Infarction
  Circulation, 1998
• Low Molecular Weight Heparin Versus Unfractionated Heparin Following Thrombolysis in Myocardial Infarction
  Journal of the American College of Cardiology, 1998